Having recognized the palmitoylation motif of APLNR, we developed a brief substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This competitive peptide, which targets the APLNR palmitoylation site together with morphine, can inhibit the development of NCP, together with pain incidence, microglial activation, and inflammatory component release https://isconolidineanopiate12097.theideasblog.com/27350004/the-best-side-of-block-pain-receptors-with-proleviate